Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 501–600 of 770
Fu, Y., Zhang, S., Zeng, X., & Qin, H. (2025) · Metabolites · doi:10.3390/metabo15040280 · Cited by 4
Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease
Hao, Y., Li, X., Zhang, Y., Zheng, J., Miao, Y., Tan, J., & Zhang, Q. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02538-1 · Cited by 4
“Increased fasting blood glucose (FBG) levels are recognized to enhance hepatic de novo lipogenesis and induce steatosis, thus facilitating the onset of NAFLD [7].”
CD47-mediated regulation of glucose and lipid metabolism: implications for the pathogenesis of MASLD
Jiang, X., Zhao, W., Shen, B., Han, Y., & Chen, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1535382 · Cited by 7
HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment
Patel, S. A., Kasem, F., Flaherty, D. T., & Barve, A. J. (2025) · BioChem · doi:10.3390/biochem5030019 · Cited by 6
Kaur, K. K. (2022) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000164 · Cited by 3
Abrahams, Y., Willmer, T., Patel, O., Samodien, E., Muller, C. J. F., Windvogel, S. L., Johnson, R., & Pheiffer, C. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.004 · Cited by 6
Cho, B. S., Fligor, S. C., Fell, G. L., Secor, J. D., Tsikis, S. T., Pan, A., Yu, L. J., Ko, V. H., Dao, D. T., Anez‐Bustillos, L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295244 · Cited by 4
Karnik, R., Vohra, A., Khatri, M., Dalvi, N., Vyas, H., Shah, H., Gohil, S., Kanojiya, S., & Devkar, R. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137843 · Cited by 4
Tao, Y., Chen, Y., Ren, J., Jiang, S., Zhang, S., Xu, H. G., & Li, Y. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.741173 · Cited by 4
Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-α
Ivashkevich, D., Ponomarenko, A., Manzhulo, I., & Dyuizen, I. (2025) · Biocell · doi:10.32604/biocell.2025.061606 · Cited by 5
“In the context of excessive sugar intake, insulin has an antilipolytic effect, encourages the synthesis and storage of TAGs in adipose tissue, and increases the fatty acid synthesis and esterification processes [13].”
Liu, R., Wang, G., Qian, Y., Jiang, Z., Wang, W., Cai, M., Zhang, S., Wang, G., Wang, C., Zou, T., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156258 · Cited by 5
Li, M., Wan, Y., Wei, Z., & Lin, W. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03856-5 · Cited by 5
“Given the important role of IR in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD), the recent Metabolic Enzymatic Score for Insulin Resistance (METS-IR) and Triglyceride-Glucose (TyG) Index can be introduced as non-invasive alternatives for assessing IR levels [24].”
Kaur, K. K. (2022) · Advances in Obesity Weight Management & Control · doi:10.15406/aowmc.2022.12.00367 · Cited by 6
Unravelling the role of obesity and lipids during tumor progression
Zhao, J., Lee, K., Toh, H. C., Lam, K., & Neo, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1163160 · Cited by 5
“While the exact causal relationships between insulin resistance and increased HCC risk is not fully understood, insulin resistance leads to increased circulating free FAs and glucose, as well as de novo lipogenesis in the hepatocytes (Smith et al., 2020).”
BackgroundMiR-143-3p/FNDC5 axis: a novel regulator of insulin sensitivity
Li, B., Dong, Y., Hu, S., & Liu, T. (2023) · Endocrine · doi:10.1007/s12020-023-03522-4 · Cited by 4
“When tissues are exposed to high glucose concentrations for a long period of time, the uptake and utilization of glucose are inhibited [14, 15].”
LaPoint, A., Singer, J., Ferguson, D., Shew, T. M., Renkemeyer, M. K., Palacios, H. H., Field, R. L., Shankaran, M., Smith, G. I., Yoshino, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.01.526676 · Cited by 4
Self-citationGrønbæk, H., Mellemkjær, A., Nielsen, S., & Magkos, F. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-552 · Cited by 4
“Hepatic DNL is directly related to circulating glucose and insulin concentrations and to intrahepatic triglyceride accumulation (7,9).”
BackgroundZheng, X., & Wang, H. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04190-6 · Cited by 3
“When insulin resistance occurs, the liver is unable to effectively inhibit fatty acid release and lipid synthesis, leading to TG deposition in the liver and subsequent fatty liver formation [27, 28].”
Mild Mitochondrial Uncoupling for True Ectopic Lipid Disposal
Lee, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167740 · Cited by 4
“Hepatic DNL and FFA uptake synergistically overload VLDL export mechanisms, further elevating circulating triglycerides and contributing to the development of NAFLD [2,6,22].”
BMI mediates the association of CALLY index with liver steatosis and fibrosis
Wen, S.-H., Tang, T., & Ye, Z.-R. (2025) · Scientific Reports · doi:10.1038/s41598-025-18919-6 · Cited by 4
Hong, S., Lee, J., Choi, S. Y., Park, J. H., & Lee, Y. G. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05091-7 · Cited by 4
“…hyperglycemia exacerbates metabolic dysregulation by promoting de novo lipogenesis, hepatic lipid accumulation, and chronic low-grade inflammation, thereby intensifying IR and contributing to the development of comorbidities, including dyslipidemia and nonal-coholic fatty liver disease [5].”
Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease
Beretta, M., Vancuylenburg, C. S., Shrestha, R., Olzomer, E. M., Osborne, B., Zhou, M., Zhang, S., Hargreaves, A., Byrne, F. L., & Hoehn, K. L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102264 · Cited by 6
“Strong evidence indicates that increased de novo lipogenesis (DNL) contributes to hepatic fat accumulation in patients with MASLD [12,13].”
Huang, C., Chen, M., Sun, Y., Zhang, L., & Liu, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1689280 · Cited by 4
Cai, Y., Nie, T., Luo, X., Wu, Y., & Wu, J. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.043 · Cited by 4
Fuentes-Barría, H., Aguilera-Eguía, R. A., Flores-Fernández, C., Angarita, L., & Alarcón-Rivera, M. (2026) · Biomedicines · doi:10.3390/biomedicines14030577 · Cited by 4
“This phenomenon, often referred to as selective hepatic insulin resistance, results in the coexistence of increased glucose production and enhanced de novo lipogenesis, thereby promoting both hyperglycemia and progressive lipid accumulation within hepatocytes [35–37].”
Yang, Q., Xu, Y., Zhang, J., Xiao, N., Lu, H., Chen, B., Yang, B., Xie, Z., & Li, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794782 · Cited by 6
“” First, toll-like receptors TLR2 and TLR4 recognize the crystal structure and recruit the intracellular adaptor protein myeloid differentiation primary response protein 88 (MyD88).”
The association between high fructose corn syrup and the development of type-2 diabetes
Almansouri, M. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1785203 · Cited by 3
“Elevated hepatic fat content increases fatty acid (FA) supply for triglyceride synthesis while inhibiting FA oxidation (32).”
Richard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
“Prolonged hyperglycemia promotes both enhanced insulin secretion and insulin resistance, together stimulating hepatic hormone sensitive lipase which breaks down TAGs stored in adipose tissue, further increasing circulating FFAs [34].”
Hu, C., Zhuang, X., Zhang, J., Wang, T., Du, S., Wang, J., Peng, X., Cao, Q., Zhang, M., & Jiang, Y. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmab118 · Cited by 6
Yang, C., Du, T., Zhao, Y., Qian, Y., Tang, J., Li, X., & Ma, L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s438652 · Cited by 3
“39 Hyperglycemia induces hepatic DNL via the transcription factor carbohydrate response-element binding protein (ChREBP).”
BackgroundPyMIDA: A Graphical User Interface for Mass Isotopomer Distribution Analysis
Ziari, N., & Hellerstein, M. K. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02211 · Cited by 3
Self-citationKwon, Y. S., Cho, Y. E., Kim, Y. S., Koh, M., & Hwang, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030151 · Cited by 7
“Enhanced de novo fatty acid synthesis is the primary factor that causes fatty liver development in humans [8].”
BackgroundYu, N.-R., Huang, S., Deng, Z., Wang, J., Shen, Y., Leng, Y., & Zhao, Q. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108132 · Cited by 3
Therapeutic Potential of Myricitrin in a db/db Mouse Model of Type 2 Diabetes
Kim, S. R., Kim, Y., Kim, H., Park, S., & Jung, U. J. (2025) · Molecules · doi:10.3390/molecules30071460 · Cited by 4
“Type 2 diabetes patients often develop MASLD [6], which is associated with an increased risk of insulin resistance [37].”
Side effects of glucocorticoids: in vivo models and underlying mechanisms
Dodonova, S. A., Михайловна, Ж. Е., Kryukov, A. A., Valiev, T. T., Kulikov, E. P., Геннадиевна, Я. М., & Lesovaya, E. A. (2025) · Discover Medicine · doi:10.1007/s44337-025-00453-z · Cited by 4
“…(2) increased blood glucose levels due to stimulation of gluconeogenesis caused by GCs [96–98]; (3) stimulation of de novo lipogenesis enhanced by high levels of glucose and insulin [99], and (4) increased release of free fatty acids from fat stores and stimulation of their liver uptake [100, 101].”
Klein, S., & Yoshino, M. (2021) · Science · doi:10.1126/science.abj7375 · Cited by 3
“It is more likely that systemic insulin resistance and its associated increases in plasma free fatty acid, glucose, and insulin concentrations are involved in the pathogenesis of hepatic steatosis in people with obesity, rather than that hepatic steatosis causes muscle insulin resistance (6, 7).”
BackgroundSelf-citationSciarrillo, C. M., Short, K. R., Keirns, B. H., Elliott, D. C., Clarke, S. L., Palle, S. K., & Emerson, S. R. (2023) · Pediatric Obesity · doi:10.1111/ijpo.13007 · Cited by 3
“34 In the present study, both adolescents with NAFLD and adolescents with obesity had lower insulin sensitivity and greater insulin secretion than adolescents with normal weight.”
Wang, B., Zhang, Y., Gai, L., He, Y., Qiu, H., & Li, P. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.7.28 · Cited by 5
“NAFLD is characterized by fatty denaturation and lipid accumulation in hepatocytes and insulin resistance (28-30).”
BackgroundBarreto, B. C., Asuzu, P., Ebenibo, S., & Dagogo-Jack, S. E. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae020 · Cited by 4
“The spectrum of MASLD includes hepatic steatosis, non-alcoholic steatohepatitis, and liver fibrosis [1-6 , 11].”
BackgroundLiu, X., Chen, H., Luo, J., He, X.-P., Zhang, W., Chen, Y., Li, X., Lan, Q.-W., Ma, X., & Guo, X. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295986 · Cited by 4
Zhou, W., Ren, S., Lu, Y., Wang, Y., Feng, L., & Gao, Q. (2024) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2024.05.527 · Cited by 3
Dietary Supplementation with Apis mellifera Wholemeal Flour Reduces Hepatic Steatosis in Obese Mice
Nascimento, A. L., Pereira, J. H. S., Caldas, B. V., Guimarães, V. H. D., Monteiro-Júnior, R. S., de Paula, A. M. B., Guimarães, A. L. S., Pereira, U. A., & Santos, S. H. S. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2023.0201 · Cited by 3
Kim, Y., Kim, J., Seo, E. J., Kim, K. T., Lee, J., Kim, J., & Kang, H. (2024) · JMIR Public Health and Surveillance · doi:10.2196/57168 · Cited by 3
“Insulin resistance is a key feature of NAFLD and is important in the pathogenesis and progression of NAFLD to nonalcoholic steatohepatitis [29,30].”
Westcott, F., Nagarajan, S. R., Parry, S. A., Savic, D., Green, C., Marjot, T., Johnson, E. M., Cornfield, T., Mózes, F. E., O’Rourke, P., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae123 · Cited by 6
“13 Previous work has shown higher frDNL in obese compared to lean individuals who had similar liver fat content, but the hepatic insulin sensitivity index was lower in the obese group, 45 supporting the concept that DNL is associated with insulin sensitivity rather than liver fat content.”
Liu, D., Yin, M., Chen, J., Fu, C., Schneider, M., Nickel, D. M., & Yao, X. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5290 · Cited by 3
“11 However, despite the correlation between the two diseases, not all patients with NAFLD develop T2DM and vice versa.”
Zheng, S., Hua, T., Yin, G., Zhang, W., Wang, X., Qi, L., Jing, X., Fan, Q., Yu, X., & Li, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1406065 · Cited by 5
Ye, J., Xie, Y., & Gong, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-19177-2 · Cited by 3
Jung, T. W., Chung, Y. H., Park, S. Y., Cho, W., Oh, H., Hacımüftüoğlu, A., El‐Aty, A. M. A., Bang, J. S., & Jeong, J. H. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105164 · Cited by 3
Yiew, N. K. H., Deja, S., Ferguson, D., Cho, K., Jarasvaraparn, C., Jácome-Sosa, M., Lutkewitte, A. J., Mukherjee, S. K., Fu, X., Singer, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.17.528992 · Cited by 3
“In NAFLD, the accumulation of excess lipid ( 5% of lean liver tissue) is largely attributed to excessive DNL 30,31 .”
Turner, R., Mukherjee, R., Wallace, M., & Sánchez-Gurmaches, J. (2023) · Journal of Visualized Experiments · doi:10.3791/64219 · Cited by 4
Si, G., Lv, X., Ge, Y., Zhang, R., Hao, D., Chen, X., Wang, C., Li, Y., Li, X., & Yuan, X. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112748 · Cited by 2
“Early AAM has been strongly linked to IR (Zhang et al., 2019), which disrupts insulin signaling, promotes lipid accumulation, and exacerbates hepatic fat deposition, creating a self-perpetuating cycle (Guerra et al., 2022; Samuel and Shulman, 2018; Smith et al., 2020).”
Gao, G., Zhang, X., Wang, Z., Xu, J., Wang, J., Liu, T., & Xie, Z. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156809 · Cited by 4
El-Naby, S. M. A., Khedr, N. F., El‐Ashmawy, N. E., & Ibrahim, A. O. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04271-z · Cited by 4
“…were explained on the basis that hyperinsulinemia in insulin-resistant states stimulates hepatic de novo lipogenesis, which represents 25% of the hepatic triglycerides accumulating in MASLD (Smith et al. 2020), and thus, insulin resistance may contribute to the hepatic steatosis observed herein.”
InfluentialMildly elevated liver lipid content is characterised by reduced insulin sensitivity
Tuomola, N., Rebelos, E., Latva‐Rasku, A., Bucci, M., Immonen, H., Saunavaara, V., Laine, S., Sjöros, T., Garthwaite, T., Raiko, J. R. H., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101535 · Cited by 5
“…and VLDL triglyceride export when HTG rises from 2 to 5%, whereas at higher HTG levels, increases in lipogenesis and triglyceride export become more gradual.40 , 41 This means that much of the metabolic derangement in lipid metabolism already occurs below the current upper limit of normal HTG.”
He, M., Zheng, H., Xie, Y., Zhang, D., Huang, W., Li, Y., Zhang, H., Deng, C., Liu, J., Song, X., et al. (2025) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaf123 · Cited by 2
Wu, J., Lai, H., Yin, J., Zhu, S., Yang, H., & Hong, H. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s526411 · Cited by 4
“These findings highlight the increasing contribution of the TyG index as OSA severity progresses.”
Mercurio, G., Giacco, A., Troise, A. D., Ledbetter, M., Pascale, S. D., Scopigno, N., Vigliotti, M., Mazzola, M., Riccio, G., Scaloni, A., et al. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70210 · Cited by 3
Association between TyG index and MASLD in lean young adults: a retrospective study
Xiao, W., Sun, X., Lv, H., Liu, X., & Zhu, J. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02029-5 · Cited by 2
“Lean MASLD is increasingly recognized as a distinct entity with unique pathophysiological features, including a strong association with insulin resistance (IR) and dysregulated glycolipid metabolism, even if the person isn’t obese [4, 5].”
NAD + in fatty liver disease: mechanistic insights and associated targets
Guo, Y.-X., Wang, Y., Wu, S., Wang, Y., & Liu, X. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10106-7 · Cited by 4
“…glucose or insulin, and liver X receptor A, thereby promoting hepatic lipid accumulation and regulating to lipid-producing genes such as Acetyl-CoA Carboxylase (ACC), Stearoyl-CoA Desaturase-1, and Fatty Acid Synthase (FASN) (Geidl-Flueck and Gerber 2023; Smith et al. 2020; Gong et al. 2023).”
Singh, G., & Aran, K. R. (2026) · Biogerontology · doi:10.1007/s10522-025-10384-y · Cited by 3
“…sex-specific results, demonstrated that males experienced earlier and rapid decreases in CA levels during cognitively normal-to-MCI progressions and faster adverse transitions to AD, whereas females exhibited slower but progressive increases in DCA levels at later disease stages (Chen et al. 2024).”
Hu, X., Chen, H., Wang, Z., Deng, Y., Huang, L., Zhang, C., Guo, L., Liu, S., & Liao, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1749989 · Cited by 2
Qiu, S., Lai, Z., Wang, Z., Zeng, J., Guo, S., Yang, L., Xie, D., Cai, Y., (15435), Y. W., Che, L., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121475 · Cited by 3
Substrate supply, compartmentation, and utilization in hepatic de novo lipogenesis
Pape, D. J., & Taylor, E. B. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.001 · Cited by 2
陶雪辉, Liu, J., Li, F., Gao, W., Luo, H., & Wang, K. (2026) · Phytotherapy Research · doi:10.1002/ptr.70298 · Cited by 2
“An increase in free fatty acids leads to hepatic insulin resistance (IR) (Smith et al. 2020), impairing glucose utilization and promoting lipid accumulation.”
Shimizu, K., Nishibata, M., Nagata, K., Hori, S., Michinaga, S., Kanehara, M., Hashimoto-Iwasaki, M., Sakurai, F., Shindou, H., Tomita, K., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202504753rr · Cited by 2
“MASLD covers a wide spectrum of liver diseases, including hepatosteatosis, liver fibrosis, cirrhosis, and hepatocellular carcinoma [4–6].”
Tricò, D., Wu, T., Cimbalo, N., Chiriacò, M., Xie, C., Sacchetta, L., Nesti, L., Gallo, S., Santoni, L., Masoni, M. C., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06730-5 · Cited by 5
“…upregulation of key transcription factors such as carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-binding protein-1c (SREBP-1c), which upregulate the expression of lipogenic enzymes such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) [35].”
Díaz, L. A., Pose, E., Israelsen, M. E., & Loomba, R. S. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01240-6 · Cited by 5
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 10
“By promoting increased rates of lipolysis, WAT insulin resistance and WAT inflammation significantly increase delivery of lipogenic substrates (glycerol and fatty acids) to the liver, which further contributes to increased gluconeogenesis and the progression of MASL to MASH 101,146,147 .”
Rahimpour, Z., Hoseini, R., & Behpour, N. (2022) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2022.277 · Cited by 2
Visualization and quantification of de novo lipogenesis using a FASN-2A-GLuc mouse model
Li, W., Zhang, S., Fu, X., Zhang, J., Li, R., Zhang, H., An, Q., Wang, W., Tian, Z., Shi, C., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-1132 · Cited by 1
Cardiovascular disease in metabolic-associated fatty liver disease
Adams, L. A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000803 · Cited by 2
“Excess adipose tissue leading to insulin resistance and subsequent increased free fatty acid inflow into the liver is typically accompanied by increased denovo hepatic lipogenesis driven by higher glucose and insulin levels [4,5].”
BackgroundZhou, T., Cao, L., Qin, L., Lu, Y., He, Y., & Tan, D. (2023) · Food Science and Technology · doi:10.1590/fst.117522 · Cited by 2
TorS ‐ Reframing a rational for type 2 diabetes treatment
Bar‐Tana, J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3712 · Cited by 2
Dawson, M. A., Hennigar, S. R., Shankaran, M., Kelley, A. M., Anderson, B. J., Nyangau, E., Field, T., Evans, W. J., Hellerstein, M. K., McClung, J. P., et al. (2023) · Physiological Reports · doi:10.14814/phy2.15885 · Cited by 2
“AT dysfunction, in combination with insulin resistance and elevated rates of hepatic DNL and cholesterol synthesis, can contribute to the development of NAFLD (Godoy-Matos et al., 2020; Sanders & Griffin, 2016).”
BackgroundMethodResultInfluentialSelf-citationLiu, B., Liu, C., Chai, X., Fan, X., Huang, T., Zhan, J., Zhu, Q., Zeng, D., Gong, Z., He, L., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c04954 · Cited by 3
Santoso, P., & Maliza, R. (2024) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2024.48257 · Cited by 2
“Additionally, YBF has been suggested to enhance the sensitivity of insulin in mice against HFD (21), while the resistance of insulin is one of the major causes of elevated fat accumulation leading to hepatic steatosis (36).”
BackgroundBurgueño, M. D. J. V., Torres Montoya, E. H., Zazueta-Moreno, J. M., Barrón‐Cabrera, E., Osuna‐Martínez, U., Urías-García, E. J., Salinas-Garza, T., Ochoa‐Acosta, D. A., & Vergara-Jiménez, M. D. J. (2024) · International Journal of Environmental Health Research · doi:10.1080/09603123.2024.2386113 · Cited by 2
Heikelä, H., Mairinoja, L., Ruohonen, S. T., Rytkönen, K. T., de Brot, S., Laiho, A., Koskinen, S., Suomi, T., Elo, L. L., Strauss, L., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400333rr · Cited by 6
Hidden metabolic effects of acetyl-CoA carboxylase inhibition
Luukkonen, P. K. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.043 · Cited by 3
Guo, Y., Shi, R., Xu, Y., Cho, W. C. S., Yang, J., Choi, Y. Y., Sun, J., Ma, Y., Pozharitskaya, O. N., Shikov, A. N., et al. (2024) · Acta Materia Medica · doi:10.15212/amm-2024-0057 · Cited by 4
Donepezil alleviates hepatic steatosis by mitigating ER stress via the AMPK/autophagy pathway
Cho, W., Choi, S. W., Lim, D. S., Gwon, H. J., El‐Aty, A. M. A., Aydemir, H. A., Hong, S. A., Jeong, J. H., & Jung, T. W. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112523 · Cited by 2
Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease
Mutlu, B., & Puigserver, P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154147 · Cited by 2
Zheng, K., Li, X., Hou, L., Gu, W., Hou, X., Wang, C., & Song, G. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0563 · Cited by 2
Contribution of de novo lipogenesis to the progression of nonalcoholic fatty liver disease
Abdul, M. M. S. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/81575 · Cited by 2
Editorial: Mitochondrial Biology and Its Role in Metabolic Diseases
Schneider, J. G., Tozzo, E., & Chakravarthy, M. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.944728 · Cited by 2
“In turn, hepatic de novo lipogenesis is promoted, diverting citrate away from the TCA cycle (4).”
BackgroundNon-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
The Effect of Probiotic Supplementation as Alternative Therapy for NAFLD: A Literature Review
Adnan, M. L. (2021) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/136328 · Cited by 2
“This condition then leads to insulin resistance which in turn re-sults in increased lipogenesis of fat in the liver and increases the risk of NAFLD [16].”
BackgroundSun, J., Lee, H. J., Lee, H. J., Park, T. Y., Heo, E. Y., Kim, D. K., & Lee, H. W. (2025) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2025.101171 · Cited by 3
Zou, Y., Wu, J., Cheng, S., Cheng, D., Chen, T., Guo, X., Tang, L., Su, X., Zhang, M., Zhang, X., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102164 · Cited by 2
“In addition, the development of MASLD is often accompanied by impaired glucose tolerance and insulin resistance [24].”
Reducing complications of metabolic dysfunction–associated steatotic liver disease
Wada, N., Iwaki, M., Kobayashi, T., Nakajima, A., & Yoneda, M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2502549 · Cited by 1
Crezzini, J., Modi, A., Cannariato, C., Caramelli, D., Ronchitelli, A., Boscato, P., Moroni, A., & Boschin, F. (2025) · Frontiers in Environmental Archaeology · doi:10.3389/fearc.2025.1558698 · Cited by 1
Zhou, Y., Yu, J., Yao, Y., Cheng, Y., Cheng, Y., Yang, R., Zeng, R., Wan, Z., Zhao, Q., Li, D., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1624848 · Cited by 2
“First, SSB is a major contributor to free sugar intake, which can lead to increased calorie consumption, high glycemic load, elevated blood glucose, hyperinsulinemia, and insulin resistance, thereby increasing LFC (38, 39).”
Liu, Y., Sun, Y., Zhou, T., Huang, X., Wang, G., & Sun, L. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107860 · Cited by 2
Hepatocyte-Specific ApoJ Knockout Improves Metabolic Profiles in the Liver of Diabetic Mice
Wang, S.-T., Li, X., Pi, J., Hsu, Y.-T., Chi, L.-C., & Sun, H.-Y. (2025) · Metabolites · doi:10.3390/metabo15120761 · Cited by 1
“Insulin resistance drives the pathogenesis of metabolic-associated steatotic liver disease (MASLD) by promoting de novo lipogenesis [16].”
ApoA5-CIDEC axis regulates hepatic lipid metabolism, inflammation, and fibrosis in MASLD
Li, C., Yang, D., Wang, X., Zhang, S., Dai, W., Zhao, S., & Zhao, W. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02619-9 · Cited by 1
“The processes of FAO, DNL, and ApoB secretion are intricately interconnected with hepatic lipid metabolism and the progression of MASLD [19, 20].”
From Anabolic to Reponic: Reclassifying Insulin’s Primary Metabolic Role
Ford, S., Bryce, D., & Moen, J. (2026) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2558
Mekki, Y. M., Park, J., Alzaareer, Z., Hussain, Z., Gulzar, A., Elzouki, A. Y. A., Güemes, A., & Zughaier, S. M. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01876-w · Cited by 1
“Another control center in the brain converted to fatty acids in the process of de novo lipogenesis (DNL) which leads to triglyceride accumulation in the liver, also called hepatic steatosis [31–34 ].”
Dohnalová, K., Kamaraj, R., Ambrož, M., Klíma, K., Chalupský, K., Bajnokova, M., Mejdrová, I., Škach, K., Hricová, J., Laštůvková, H., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119168 · Cited by 1
Immunometabolism of IRF4 in adipose, muscle, and immune cells influences obesity and MASLD
Marko, D. M., & Schertzer, J. D. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00554.2025 · Cited by 1
Treviño, S., Fuentes‐Medel, E., Venegas, B., Muñoz‐Arenas, G., Vázquez‐Roque, R. A., Galindo-Ramírez, F., Avelino-Cruz, J. E., Flores, G., Guevara, J., & Díaz, A. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02501-4 · Cited by 2
“The observed metabolic dysfunction proves that the body has entered a state of metabolic disorder (Vollenweider et al. 2015, Softic et al. 2016, Smith et al. 2020).”
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.